arGentis Expands Scientific Advisory Board

arGentis Pharmaceuticals, LLC announced today that the company has added new members to its Scientific Advisory Board overseeing development of autoimmune related therapies.

Dr. Arnold Postlethwaite, Chief Medical Officer and Chairman of arGentis Pharmaceutical's Scientific Advisory Board stated, "Our post Phase II data analysis, along with the discovery of a genetic marker highly associated with the induction of oral immune tolerance in systemic sclerosis patients, have opened the door for additional study and development of ARG201 as an effective immunoregulatory therapy. I am extremely pleased that my colleagues, Drs. Mayes, Furst, Steen and Wong will be joining me in advising arGentis Pharmaceuticals on these exciting developments and their paths to commercialization."

 

Comments

Popular posts from this blog

Trump wants more mental health care; Alabama says it's trying

Smokefree Mumbai campaign responds to recent study by BCM, Houston that claims smoking create stronger memory